Literature DB >> 14576132

Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole.

Rama Ramani1, Madhurama Gangwar, Vishnu Chaturvedi.   

Abstract

Aspergillus fumigatus isolates were tested with three antifungals by flow cytometry (FC) and fluorescence-activated cell sorting. FC results after 4 h correlated well with MICs obtained by the NCCLS M38-A method; voriconazole exhibited fungicidal activity, albeit to a lesser extent than amphotericin B, but to a greater extent than itraconazole.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576132      PMCID： PMC253779          DOI： 10.1128/AAC.47.11.3627-3629.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Early events in macrophage killing of Aspergillus fumigatus conidia: new flow cytometric viability assay.

Authors:  K A Marr; M Koudadoust; M Black; S A Balajee
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

2.  Caspofungin (Cancidas) for aspergillosis.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2001-07-09       Impact factor: 1.909

Review 3.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

6.  Colorimetric assay for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; J P Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

7.  Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; S Nangia; J H Rex
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

8.  Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

Authors:  C Lass-Flörl; M Nagl; C Speth; H Ulmer; M P Dierich; R Würzner
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

10.  Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level.

Authors:  B Jahn; A Rampp; C Dick; A Jahn; M Palmer; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more
  7 in total

1.  In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

Authors:  Susanne Perkhofer; Cornelia Mrazek; Lukas Hartl; Cornelia Lass-Flörl
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

2.  Hitting the caspofungin salvage pathway of human-pathogenic fungi with the novel lasso peptide humidimycin (MDN-0010).

Authors:  Vito Valiante; Maria Cândida Monteiro; Jesús Martín; Robert Altwasser; Noureddine El Aouad; Ignacio González; Olaf Kniemeyer; Emilia Mellado; Sara Palomo; Nuria de Pedro; Ignacio Pérez-Victoria; José R Tormo; Francisca Vicente; Fernando Reyes; Olga Genilloud; Axel A Brakhage
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry.

Authors:  Cidália Pina-Vaz; Sofia Costa-de-Oliveira; Acácio G Rodrigues; Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Evaluations of shorter exposures of contact lens cleaning solutions against Fusarium oxysporum species complex and Fusarium solani species complex to simulate inappropriate usage.

Authors:  Rama Ramani; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

5.  Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology.

Authors:  Joseph Meletiadis; Charalampos Antachopoulos; Theodouli Stergiopoulou; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  Human dendritic cells following Aspergillus fumigatus infection express the CCR7 receptor and a differential pattern of interleukin-12 (IL-12), IL-23, and IL-27 cytokines, which lead to a Th1 response.

Authors:  Valérie Gafa; Roberto Lande; Maria Cristina Gagliardi; Martina Severa; Elena Giacomini; Maria Elena Remoli; Roberto Nisini; Carlo Ramoni; Paolo Di Francesco; Delphine Aldebert; Renée Grillot; Eliana M Coccia
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

7.  Application of fluorescent probes to study structural changes in Aspergillus fumigatus exposed to amphotericin B, itraconazole, and voriconazole.

Authors:  Madhurama Gangwar; Richard Cole; Rama Ramani; Daniel J Sheehan; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2006-08       Impact factor: 3.785
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.